Danaher Corporation $DHR Shares Purchased by Phraction Management LLC

by · The Markets Daily

Phraction Management LLC grew its position in Danaher Corporation (NYSE:DHR – Free Report) by 39.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,802 shares of the conglomerate’s stock after purchasing an additional 18,620 shares during the quarter. Danaher makes up 3.8% of Phraction Management LLC’s investment portfolio, making the stock its 9th largest position. Phraction Management LLC’s holdings in Danaher were worth $13,046,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in DHR. Norges Bank acquired a new stake in shares of Danaher in the 2nd quarter valued at about $1,979,503,000. Viking Global Investors LP increased its stake in Danaher by 543.9% in the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after buying an additional 2,455,994 shares during the period. Generation Investment Management LLP lifted its position in Danaher by 56.2% in the second quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the period. Primecap Management Co. CA raised its position in Danaher by 924.2% in the second quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock worth $244,815,000 after acquiring an additional 1,118,318 shares in the last quarter. Finally, Baird Financial Group Inc. increased its holdings in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after purchasing an additional 1,072,617 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.8%

Shares of DHR stock opened at $224.43 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The business’s fifty day moving average is $219.93 and its 200-day moving average is $206.66. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The stock has a market cap of $158.53 billion, a PE ratio of 46.28, a price-to-earnings-growth ratio of 4.32 and a beta of 0.89.

Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the business posted $1.71 earnings per share. Danaher’s revenue was up 4.4% compared to the same quarter last year. Equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Jefferies Financial Group boosted their price objective on shares of Danaher from $245.00 to $255.00 and gave the stock a “buy” rating in a research report on Wednesday. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Bank of America cut their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. KeyCorp reissued an “overweight” rating on shares of Danaher in a research report on Thursday. Finally, Evercore ISI upped their target price on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Twenty-one investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $248.25.

Check Out Our Latest Stock Analysis on DHR

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the sale, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 30,248 shares of company stock worth $6,609,663. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Articles

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).